MedTrace Logo

Understanding Risk Factors Involved in Developing a Second Blood Clot.

NCT00261014 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2015-11-18

No results posted yet for this study

Summary

The purpose of this study is to develop a way to predict which patients diagnosed with idiopathic blood clots can safely stop warfarin therapy after six months. We will use patient characteristics, blood test results and imaging test results to identify those patients who have the lowest risk of developing a new blood clot after warfarin is stopped.

Conditions

  • Deep Vein Thrombosis

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Biomerieux inc

    collaborator INDUSTRY

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Marc Rodger, MD MSc · OHRI

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Canada
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00261014 on ClinicalTrials.gov